MedChem & Industry Collaborator Pipeline

Our laboratory, from time to time, negotiates with industry to advance lead compounds into preclinical or advanced late stage models. If you are in industry and are interested in technology transfer, intellectual property rights, or technology licensing from the Njoo lab, email edward.njoo@asdrp.org.

Technology Transfers must be performed in accordance to ASDRP's policies on patenting and publishing student-derived research, and are jointly negotiated by our legal team and the legal team of an industrial collaborator.

Reverse Logic Linkers for Self-Regulating Drug Delivery

Collaboration with: J. T. Sarkar, PhD; ReThink64 Bionetworks PBC, Stanford University

Currently: US Patent filed in January 2024 (collaboration with industry and with Yamamoto lab), advanced organoid studies underway.

Technology Patent: Sarkar, Jay Tapash; Njoo, Edward; Xia, Lorelei*; Yamamoto, Akira; Bashkin, Zachary*; Chang, Warren*. "Auto-Tuning Drug Regulator Constructs". US Patent App. PCT/US2024/011827, WIPO WO2024155707A1

[Google Patent Link]

*Denotes student co-inventor.

Prodrugs of Bufadienolide Natural Products for Selective Breast Cancer Targeting

Collaboration with:

Feng Wang-Johanning, MD, PhD & Gary Johanning, PhD
SunnyBay Biotech Co.

Currently: Preclinical (in vivo) models underway

Real time reaction monitoring with benchtop nuclear magnetic resonance (NMR) spectroscopy

Collaboration with:

Nanalysis Corp. - See literature

Currently: Two application notes / white papers published.

See Sarah Su, "Quantitative analysis of singlet oxygen production via a 4+2 endoperoxide cycloaddition by 1H benchtop nuclear magnetic resonance spectroscopy" Nanalysis Application Note (2022)

See Xina Wang, "Quantitative 19F Benchtop NMR provides mechanistic insight for the optimization of the chemical synthesis of Carmofur" Nanalysis Application Note (2023)

For representative publications, see Chyu, et al. Spectroscopy J. 2024; Gu, et al. BioRXiv 2024; Wang, et al. Canadian J. Chem. 2023, Chen, et al. ACS Omega 2023; Su, et al. J. Emerg. Invest. 2021

Antibody-Drug Conjugates with Engineered Topoisomerase Inhibitors

Collaboration with:

Feng Wang-Johanning, MD, PhD & Gary Johanning, PhD
SunnyBay Biotech Co.

Currently: Preclinical (in vivo) models underway

Engineered peptide-lipid constructs for mRNA delivery for prophylactic cancer vaccination

Collaboration with:

Feng Wang-Johanning, MD, PhD & Gary Johanning, PhD
SunnyBay Biotech Co.

Currently: Preclinical (in vivo) models underway